-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Leiomyosarcoma (LMS) and liposarcoma (LPS) express PD-L1, but are often resistant to PD-1/PD-L1 inhibitors (ICIs)
.
Trabectedin, a tetrahydroisoquinoline alkaloid with potent antitumor activity, is currently PDA approved for the treatment of leiomyosarcoma and liposarcoma
This study is a single-arm, open-label, Phase 1/2 trial to evaluate the efficacy and safety of trabectedin in combination with the anti-PD-L1 antibody Avelumab in the treatment of advanced leiomyosarcoma and liposarcoma
.
.
The Phase 1 phase evaluated the safety and feasibility of trabectedin (1, 1.
2, and 1.
5 mg/m2) in combination with standard-dose Avelumab
.
The primary endpoint of the Phase 2 phase was objective response rate (ORR)
Grade 3-5 Treatment-Related Adverse Reactions
Grade 3-5 treatment-related adverse reactions
Grade 3-5 treatment-related adverse reactions
A total of 33 patients were recruited: 24 leiomyosarcoma (6 uterine sarcoma, 18 non-uterine sarcoma) and 11 liposarcoma
.
In Phase 1, two dose-limiting toxicities were observed in each of six patients in the 1.
2 mg/m2 and 1.
5 mg/m2 dose groups of trabectedin
The recommended dose for Phase 2 is trabectedin 1.
The 6-month progression-free survival rate was 52%, and the median progression-free survival was 8.
Previous studies in which progression-free survival was superior to trabectedin deserves further investigation
Original source:
Original Source: Original Source:Wagner Michael J, Zhang Yuzheng, Cranmer Lee D et al.
Wagner Michael J, Zhang Yuzheng, Cranmer Lee D et al.
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
[J] .
Clin Cancer Res, 2022, https://doi.
org/10.
1158/1078 -0432.
CCR-22-0240.
Leave a message here